Search Results - "Chan, Kelvin K."

Enhancing Outpatient Symptom Management in Patients With Head and Neck Cancer: A Qualitative Analysis by Noel, Christopher W, Du, Yue Jennifer, Baran, Elif, Forner, David, Husain, Zain, Higgins, Kevin M, Karam, Irene, Chan, Kelvin K W, Hallet, Julie, Wright, Frances, Coburn, Natalie G, Eskander, Antoine, Gotlib Conn, Lesley

“…Patients with head and neck cancer manage a variety of symptoms at home on an outpatient basis. Clinician review alone often leaves patient symptoms undetected…”
Get more information

Should Basket Trials Be Pathways to Drug Registration for Biomarker-Defined Subgroups of Advanced Cancers? by Chan, Kelvin K-W, Tannock, Ian F

Get full text

Fracture risk among patients with cancer compared to individuals without cancer: a population-based study by Gong, Inna Y., Chan, Kelvin K. W., Lipscombe, Lorraine L., Cheung, Matthew C., Mozessohn, Lee

“…Background Patients with cancer may be at increased risk of osteoporosis and fracture; however, gaps exist in the existing literature and the association…”
Get full text

Do female and male patients derive similar benefits from approved systemic oncology therapies? A systematic review and meta-analysis by Arciero, Vanessa, McDonald, Erica, Nguyen, Vivian, Saluja, Ronak, Raphael, Michael, Parmar, Ambica, Chan, Kelvin K. W.

“…Purpose The National Institutes of Health’s policy for the inclusion of females in clinical research was a pivotal step towards the consideration of sex as a…”
Get full text

Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for Melanoma by Bateni, Sarah B, Nguyen, Paul, Eskander, Antoine, Seung, Soo Jin, Mittmann, Nicole, Jalink, Matthew, Gupta, Arjun, Chan, Kelvin K W, Look Hong, Nicole J, Hanna, Timothy P

“…Melanoma treatment has evolved during the past decade with the adoption of adjuvant and palliative immunotherapy and targeted therapies, with an unclear impact…”
Get more information

Cancer treatment-related financial toxicity experienced by patients in low- and middle-income countries: a scoping review by Udayakumar, Suji, Solomon, Eden, Isaranuwatchai, Wanrudee, Rodin, Danielle L., Ko, Yoo-Joung, Chan, Kelvin K. W., Parmar, Ambica

“…Purpose In the past decade, literature has called attention to financial toxicities experienced by cancer patients. Though studies have addressed research…”
Get full text

Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes by Gong, Inna Y., Yan, Andrew T., Earle, Craig C., Trudeau, Maureen E., Eisen, Andrea, Chan, Kelvin K. W.

“…Purpose Little data exist for comparing cardiac safety and survival outcomes of trastuzumab/pertuzumab or ado-T emtansine (TDM1) in metastatic breast cancer…”
Get full text

Power and sample size calculation for incremental net benefit in cost effectiveness analyses with applications to trials conducted by the Canadian Cancer Trials Group by Everest, Louis, Chen, Bingshu E, Hay, Annette E, Cheung, Matthew C, Chan, Kelvin K W

“…Historically, a priori power and sample size calculations have not been routinely performed cost-effectiveness analyses (CEA), partly because the absence of…”
Get full text

Phase-specific and lifetime costs of cancer care in Ontario, Canada by de Oliveira, Claire, Pataky, Reka, Bremner, Karen E, Rangrej, Jagadish, Chan, Kelvin K W, Cheung, Winson Y, Hoch, Jeffrey S, Peacock, Stuart, Krahn, Murray D

“…Cancer is a major public health issue and represents a significant economic burden to health care systems worldwide. The objective of this analysis was to…”
Get full text

Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials by Popovic, Marko, Warr, David G., DeAngelis, Carlo, Tsao, May, Chan, Kelvin K. W., Poon, Michael, Yip, Cheryl, Pulenzas, Natalie, Lam, Henry, Zhang, Liying, Chow, Edward

“…Purpose Palonosetron, a 5-hydroxytryptamine 3 receptor antagonist (5-HT 3 RA) with a strong binding affinity and long half-life, has been used in numerous…”
Get full text

Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening by Visram, Alissa, Chan, Kelvin K W, McGee, Phyllis, Boro, Jordana, Hicks, Lisa K, Feld, Jordan J

“…Reactivation of hepatitis B virus (HBV) during immunosuppressive therapy (IST) can lead to severe and even fatal hepatitis but can be largely prevented with…”
Get full text

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada by Beca, Jaclyn M, Walsh, Shaun, Raza, Kaiwan, Hubay, Stacey, Robinson, Andrew, Mow, Elena, Keech, James, Chan, Kelvin K W

“…While no direct comparative data exist for crizotinib in ROS1+ non-small cell lung cancer (NSCLC), studies have suggested clinical benefit with this targeted…”
Get full text

Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada by Ezeife, Doreen A., Kirk, Veronica, Chew, Derek S., Nixon, Nancy A., Lee, Roy, Le, Lisa W., Chan, Kelvin K.-W., Leighl, Natasha B.

“…•Osimertinib is effective for treating lung cancer with an EGFR mutation.•The cost-effectiveness of osimertinib in a public payer system was assessed.•At the…”
Get full text

Health technology assessment methodology in metastatic renal cell carcinoma by Parmar, Ambica, Chan, Kelvin K. W.

“…Cancer care is currently experiencing rapid development in novel therapeutics, with an associated rise in treatment costs. These changes not only create a…”
Get full text

Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta‐analysis by Chan, Kelvin K. W., Saluja, Ronak, Delos Santos, Keemo, Lien, Kelly, Shah, Keya, Cramarossa, Gemma, Zhu, Xiaofu, Wong, Rebecca K.S.

“…The relative survival benefits and postoperative mortality among the different types of neoadjuvant treatments (such as chemotherapy only, radiotherapy only or…”
Get full text

Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting by Thein, Hla-Hla, Qiao, Yao, Zaheen, Ahmad, Jembere, Nathaniel, Sapisochin, Gonzalo, Chan, Kelvin K W, Yoshida, Eric M, Earle, Craig C

“…Hepatocellular carcinoma (HCC) presentation is heterogeneous necessitating a variety of therapeutic interventions with varying efficacies and associated…”
Get full text

Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study by Beca, Jaclyn M, Chan, Kelvin K W, Naimark, David M J, Pechlivanoglou, Petros

“…Extrapolation of time-to-event data from clinical trials is commonly used in decision models for health technology assessment (HTA). The objective of this…”
Get full text

Impact of body mass index on survival in women receiving chemotherapy for early breast cancer by Pezo, Rossanna C., Chan, Kelvin K. W., Mata, Danilo Giffoni M. M., Menjak, Ines, Eisen, Andrea, Trudeau, Maureen

“…Purpose The impact of elevated body mass index (BMI) on overall survival (OS) in patients receiving modern anthracycline-taxane chemotherapy for early breast…”
Get full text

Assessing the efficacy‐effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population‐based, real‐world data for contemporary parenteral cancer therapeutics by Phillips, Cameron M., Parmar, Ambica, Guo, Helen, Schwartz, Deborah, Isaranuwatchai, Wanrudee, Beca, Jaclyn, Dai, Wei, Arias, Jessica, Gavura, Scott, Chan, Kelvin K. W.

“…Background Although increasing evidence has suggested that an efficacy‐effectiveness gap exists between clinical trial (CT) and real‐world evidence (RWE), to…”
Get full text

Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada by Blanchette, Phillip S., Lam, Melody, Richard, Lucie, Allen, Britney, Shariff, Salimah Z., Vandenberg, Ted, Pritchard, Kathleen I., Chan, Kelvin K. W., Louie, Alexander V., Desautels, Danielle, Raphael, Jacques, Earle, Craig C.

“…Purpose Adherence to adjuvant endocrine therapy among post-menopausal breast cancer patients is an important survivorship care issue. We explored factors…”
Get full text